The immunomodulation to diabetes control: New proposals for the reversion of this disease

Autor(es)

Mancio, Rafael Dias ; Minatel, Elaine ; Cardoso, Mauricio de Almeida ; Khan, Barkat Ali ; Caldeira, Eduardo Jose

• Tipo de documento: Artigo Científico
• Fonte: DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS; v. 9, n. 4, p. 210-212, OCT-DEC 2015.
• Citações Web of Science: 1

Resumo

The diabetes mellitus is a metabolic disorder, characterized by the hyperglycemia with deficiency in the use of carbohydrates, fats and proteins, resultant of the impairment in secretion and/or insulin action. Severely, the type 1 diabetes provokes the compromise of several organs, causing different disorders and until death of patient. In this way, the literature has shown the general treatments for the type 1 diabetes and currently the focus in immunotherapy and/or immunomodulation, to control of this hyperglycemic condition. The use of new therapies is necessary due to the high increase of incidence of this disease around the world. Recent studies showed an increase of 40% in the cases since 1997. This disease affects different organs, including the glandular tissues, mainly the pancreas. Despite all therapies for diabetes control, the damages occurred remain irreversible. Thus, in addition to general treatments, the use of immunotherapy may open new perspectives for treatment of this disease. Within this aspect, the anti-CD3 monoclonal antibodies may be effective, mainly by protect and maintain the pancreatic acinar cells. Thus, these treatments based in the immunomodulation can be an option for diabetes control and to reverse the damage caused by this disease. (C) 2015 Diabetes India. Published by Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 10/05455-8 - Efeitos do tratamento com anti-CD3 (OKT3) sobre as glândulas salivares de camundongos diabéticos espontâneos
• Beneficiário: Hugo Tadeu Metidieri
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 10/51619-2 - Influencia do tratamento com okt-3 e mko-431 sobre a expressao dos receptores de insulina em glandulas salivares de camundongos espontaneamente diabeticos.
• Beneficiário: Eduardo José Caldeira
• Modalidade de apoio: Auxílio à Pesquisa - Regular